newsfilter
← Latest News
GlobeNewswire·

Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data

  • Vaxcyte appointed Luis Jodar, Ph.D. as Chief Medical Officer and David McAvoy, J.D. as Chief Legal Officer.
  • Luis Jodar previously served as Pfizer's Chief Medical Officer for Vaccines and Infectious Diseases, leading development for Prevnar 13 & Prevnar 20.
  • David McAvoy joins from Teva, where he served as Chief Legal Officer after holding senior legal roles at Eli Lilly, Brickell Biotech, & Endocyte.
  • Topline safety, tolerability, & immunogenicity data from the VAX-31 adult Phase 3 OPUS-1 pivotal trial are now expected by the end of October 2026.
  • The OPUS-1 trial data announcement narrows previous guidance from the fourth quarter of 2026 to late October 2026.
  • Vaxcyte plans to announce data from the OPUS-2 & OPUS-3 Phase 3 trials in the first half of 2027.
  • The OPUS program includes three fully enrolled trials with 6,191 adults dosed to support a potential Biologics License Application submission for VAX-31.
  • VAX-31 is a 31-valent pneumococcal conjugate vaccine candidate designed to prevent invasive pneumococcal disease & pneumonia.
  • The company also develops VAX-24, VAX-XL, VAX-A1, & VAX-GI candidates using its proprietary XpressCF cell-free protein synthesis platform.